These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 32508818)

  • 1. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
    Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
    J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
    Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A very long-acting IL-15: implications for the immunotherapy of cancer.
    Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
    Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
    J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
    Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
    Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
    Chen W; Bamford RN; Edmondson EF; Waldmann TA
    Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
    Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-15 in the treatment of cancer.
    Waldmann TA
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1689-701. PubMed ID: 25359408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Human Interleukin-15 and Anti-PD-L1 Combination Therapy Expands a CXCR3+PD1-/low CD8 T-Cell Subset in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Chen P; Chen H; Moussa M; Cheng J; Li T; Qin J; Lifson JD; Sneller MC; Krymskaya L; Godin S; Lane HC; Catalfamo M
    J Infect Dis; 2020 Feb; 221(4):523-533. PubMed ID: 31562760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
    Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
    Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.
    Conlon KC; Potter EL; Pittaluga S; Lee CR; Miljkovic MD; Fleisher TA; Dubois S; Bryant BR; Petrus M; Perera LP; Hsu J; Figg WD; Peer CJ; Shih JH; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    Clin Cancer Res; 2019 Aug; 25(16):4945-4954. PubMed ID: 31142503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 15 as a promising candidate for tumor immunotherapy.
    Jakobisiak M; Golab J; Lasek W
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
    Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.